Skip to content
10-Q

Quarterly Report

Evommune, Inc. EVMN

0001193125-26-211963

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 5, 2026 36.02M sh
Shares Diluted Q1 2026 · Mar 31, 2026 33.67M sh
Shares Diluted Q1 2026 · Mar 31, 2025 1.53M sh
Capex Q1 2026 · Mar 31, 2026 $83K
Capex Q1 2026 · Mar 31, 2025 $0
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$27.5M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$23.9M
Short Term Investments Q1 2026 · Mar 31, 2026 $163.15M
Short Term Investments Q1 2026 · Dec 31, 2025 $105.14M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $48.32M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $44.06M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $5.7M
Stockholders Equity Q1 2026 · Mar 31, 2026 $304.56M
Stockholders Equity Q1 2026 · Dec 31, 2025 $205.57M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$158.24M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$144.24M
Current Liabilities Q1 2026 · Mar 31, 2026 $10.6M
Current Liabilities Q1 2026 · Dec 31, 2025 $17.91M
Total Liabilities Q1 2026 · Mar 31, 2026 $17.9M
Total Liabilities Q1 2026 · Dec 31, 2025 $19.38M
Current Assets Q1 2026 · Mar 31, 2026 $215.86M
Current Assets Q1 2026 · Dec 31, 2025 $153.48M
Total Assets Q1 2026 · Mar 31, 2026 $322.46M
Total Assets Q1 2026 · Dec 31, 2025 $224.95M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.64
Eps Diluted Q1 2026 · Mar 31, 2025 −$9.48
Eps Basic Q1 2026 · Mar 31, 2026 −$0.64
Eps Basic Q1 2026 · Mar 31, 2025 −$9.48
Sga Expense Q1 2026 · Mar 31, 2026 $6.64M
Sga Expense Q1 2026 · Mar 31, 2025 $3.67M
Rd Expense Q1 2026 · Mar 31, 2026 $17.32M
Rd Expense Q1 2026 · Mar 31, 2025 $14.36M
Net Income Q1 2026 · Mar 31, 2026 −$21.67M
Net Income Q1 2026 · Mar 31, 2025 −$14.56M
Operating Income Q1 2026 · Mar 31, 2026 −$23.95M
Operating Income Q1 2026 · Mar 31, 2025 −$15.03M
Revenue Q1 2026 · Mar 31, 2026 $0
Revenue Q1 2026 · Mar 31, 2025 $3M